Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.77 |
| ▸ | HTT | P42858 | 2/20 | 0.77 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.77 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.77 |
| ▸ | MEN1 | O00255 | 4/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.69 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | CTSD | P07339 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | SLC12A2 | P55011 | 1/20 | 0.64 |
| ▸ | SLC12A5 | Q9H2X9 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methyl Alcohol SCHEMBL4957272 | 0.97 | GAA (0.73) | GAASMN1; SMN2HTTNCOA1NCOA3 | |
| SCHEMBL4958310 | 0.92 | GAA (0.71) | GAASMN1; SMN2HTTNCOA1NCOA3 | |
| SCHEMBL4958300 | 0.92 | GAA (0.71) | GAASMN1; SMN2HTTNCOA1NCOA3 | |
| SCHEMBL94829 | 0.89 | GAA (0.71) | GAASMN1; SMN2HTTNCOA1NCOA3 | |
| SCHEMBL27657640 | 0.89 | GAA (0.71) | GAASMN1; SMN2HTTNCOA1NCOA3 | |
| SCHEMBL6814805 | 0.87 | GAA (0.69) | GAASMN1; SMN2HTTNCOA1NCOA3 | |
| SCHEMBL5226448 | 0.87 | MAPT (0.78) | GAASMN1; SMN2HTTNCOA1NCOA3 | |
| SCHEMBL1010241 | 0.87 | GAA (0.69) | GAASMN1; SMN2HTTNCOA1NCOA3 | |
| SCHEMBL8114708 | 0.87 | SMN1; SMN2 (1.00) | GAASMN1; SMN2HTTNCOA1NCOA3 | |
| SCHEMBL394290 | 0.87 | MEN1 (0.65) | GAASMN1; SMN2HTTNCOA1NCOA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115108930-A | Synthetic method and application of aminophenyl benzamide compound | 合肥工业大学 | 2022-09-27 | — | — | CN | claimed |
| CN-108409674-A | A kind of preparation method of Ai Dailalisi intermediates | 南京法恩化学有限公司 | 2018-08-17 | — | — | CN | claimed |
| US-7539006-B2 | Electrolytic solution for driving electrolytic capacitor and electrolytic capacitor | RUBYCON CORPORATION (JP) | 2009-05-26 | — | — | US | claimed |
| US-20070029529-A1 | Electrolytic solution for driving electrolytic capacitor and electrolytic capacitor | KOMATSU AKIHIKO | 2007-02-08 | — | — | US | claimed |
| US-20040245105-A1 | Electrolyte solution for driving electrolytic capacitor and electrolytic capacitor | RUBYCON CORPORATION (JP) | 2004-12-09 | — | — | US | claimed |
| EP-1437749-A1 | ELECTROLYTE SOLUTION FOR DRIVING ELECTROLYTIC CAPACITOR AND ELECTROLYTIC CAPACITOR | Rubycon Corporation (JP) | 2004-07-14 | — | — | EP | claimed |
| EP-0670855-A1 | NITRO OR NITROSO GROUP TERMINATED MESOGENIC EPOXY RESIN ADDUCTS | THE DOW CHEMICAL COMPANY (US) | 1995-09-13 | — | — | EP | claimed |
| WO-1994012555-A1 | NITRO OR NITROSO GROUP TERMINATED MESOGENIC EPOXY RESIN ADDUCTS | THE DOW CHEMICAL COMPANY (US) | 1994-06-09 | — | — | WO | claimed |
| US-3969510-A | BENZAMIDE | BADISCHE ANILIN- & SODA-FABRIK AKTIENGESELLSCHAFT (DT) | 1976-07-13 | — | — | US | claimed |
| EP-4622964-A1 | QUINAZOLINONE DERIVATIVES FOR HDAC INHIBITION | Gilva Therapeutics Co., Ltd. (TW) | 2025-10-01 | — | — | EP | disclosed |
| WO-2025085669-A1 | QUINAZOLINONE DERIVATIVES FOR HDAC INHIBITION | GILVA THERAPEUTICS CO., LTD. (CN) | 2025-04-24 | — | — | WO | disclosed |
| US-12065421-B2 | Inhibitors of oplophorus luciferase-derived bioluminescent complexes | PROMEGA CORPORATION (US) | 2024-08-20 | — | — | US | disclosed |
| EP-4140991-B1 | INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES | PROMEGA CORP (US) | 2024-05-15 | — | — | EP | disclosed |
| EP-4140991-A1 | INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES | Promega Corporation (US) | 2023-03-01 | — | — | EP | disclosed |
| US-5047573-A | Process for the production of peptides using diacylamines | BRADACZEK HANS (DE) | 1991-09-10 | — | — | US | disclosed |
| EP-0259396-B1 | PROCESS FOR PEPTIDE PRODUCTION | BRADACZEK, Hans (DE) | 1991-07-24 | — | — | EP | disclosed |
| EP-0259396-A1 | PROCESS FOR PEPTIDE PRODUCTION. | BRADACZEK HANS (DE) | 1988-03-16 | — | — | EP | disclosed |
| WO-1987005292-A1 | PROCESS FOR PEPTIDE PRODUCTION | BRADACZEK HANS (DE) | 1987-09-11 | — | — | WO | disclosed |
| US-4123554-A | Fungicidal and germicidal benzanilides | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 1978-10-31 | — | — | US | disclosed |
| US-4004029-A | BENZAMIDES | THE UPJOHN COMPANY (US) | 1977-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12065421-B2 | Inhibitors of oplophorus luciferase-derived bioluminescent complexes | LUC7L2, LYPLAL1, GUSB | GAA 937/4885SMN1; SMN2 2491/4885HTT 3910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.